Very late-onset membranous nephropathy secondary to alemtuzumab in a patient with multiple sclerosis
Nefropatía membranosa muy tardía secundaria a alemtuzumab en paciente con esclerosis múltiple
Área salud
Consenso de expertos sobre el uso de alemtuzumab en la práctica clínica diaria en España
Introducción Alemtuzumab es un fármaco de alta eficacia aprobado por la Agencia Europea de Medicamentos como tratamiento modificador de la enfermedad en pacientes con esclerosis múltiple remitente recurrente. Objetivo Elaborar un documento de consenso sobre […]
Área salud
Relationship between inflammation and oxidative stress and its effect on multiple sclerosis
Introduction This paper highlights the relationship of inflammation and oxidative stress as damage mechanisms of Multiple Sclerosis (MS), considered an inflammatory and autoimmune disease. Development The oxidative stress concept has been defined by an imbalance […]
Área salud
Association of depression in multiple sclerosis with fatigue, sleep disturbances, disability, and health-related quality of life: Outcomes of a cross-sectional study
Introduction Depression affect individuals with multiple sclerosis (MS) more frequently compared with the general population. It can worsen the symptoms of MS, influence disability progression, and significantly reduce the quality of life (QoL). Method We […]